Journal article
Genetic variants in the regulatory t cell-related pathway and colorectal cancer prognosis
S Neumeyer, X Hua, P Seibold, L Jansen, A Benner, B Burwinkel, N Halama, SI Berndt, AI Phipps, LC Sakoda, RE Schoen, ML Slattery, AT Chan, M Gala, AD Joshi, S Ogino, M Song, E Herpel, H Blaker, M Kloor Show all
Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2020
Abstract
Background: High numbers of lymphocytes in tumor tissue, including T regulatory cells (Treg), have been associated with better colorectal cancer survival. Tregs, a subset of CD4 T lymphocytes, are mediators of immunosuppression in cancer, and therefore variants in genes related to Treg differentiation and function could be associated with colorectal cancer prognosis. Methods: In a prospective German cohort of 3,593 colorectal cancer patients, we assessed the association of 771 single-nucleotide polymorphisms (SNP) in 58 Treg-related genes with overall and colorectal cancer-specific survival using Cox regression models. Effect modification by microsatellite instability (MSI) status was also i..
View full abstractRelated Projects (3)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
CPS-II: The authors thank the CPS-II participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the NCI Surveillance Epidemiology and End Results program. CCFR: We graciously thank the generous contributions of our study participants, the dedication of study staff, and the financial support from the U.S. NCI, for without each of these this important registry would not exist. DACHS: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR1704/6-4, CH 117/1-1, HO5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, and BR 1704/17-1); the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, and 01ER1505B); the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany; and German Cancer Research Center. Fred Hutch core grant: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704 awarded to T. Lynch. Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO): NCI, NIH, U.S. Department of Health and Human Services (U01 CA137088; R01 CA059045 and R01 CA248857 to U. Peters and R01 CA176272 to P.A. Newcomb). DALS: NIH (R01 CA48998 to M.L. Slattery). Harvard cohorts (HPFS, NHS, PHS): HPFS is supported by the NIH (P01 CA055075 to E. Giovannucci, UM1 CA167552 to W. Willett, U01 CA167552 to W. Willett, R01 CA137178 to A.T. Chan, R01 CA151993 and R35CA197735 to S. Ogino), NHS by the NIH (R01 CA137178 to A.T Chan, P01 CA087969 to E. Giovannucci, UM1 CA186107 to M. Stampfer, R01 CA151993 and R35 CA197735 to S. Ogino), and PHS by the NIH (R01 CA042182 to M. Stampfer). Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. CPS-II: The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study II (CPS-II) cohort. This study was conducted with Institutional Review Board approval.